Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups

Código QR

Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups

DCCT (Diabetes Control and Complications Trial) study established that intensified insulin therapy in multiple daily injections (MDI) or continuous insulin infusion (CSII) regimens substantially reduce both development and progression of complications in patients with type 1 diabetes mellitus (T1DM)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Natalya Nikitichna Volevodz, Dmitriy Nikitich Laptev, Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2013
Materias:	diabetes mellitus insulin analogues hypoglycemia Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/e2aff6d78bf2450a90afabf1468d9f15
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Comparative efficacy assessment for various insulin regimens in patients with type 2 diabetes mellitus, ischaemic heart disease and frequent hypoglycemic events
por: Vladimir Ivanovich Kudinov, et al.
Publicado: (2012)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014)

Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
por: Vadim Valer'evich Klimontov, et al.
Publicado: (2014)

Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2015)

On the safety of insulin Glargine
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009)

The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
por: M. V. Shestakova, et al.
Publicado: (2021)

Modern basal insulins: an ongoing story or the start of a new era?
por: Ivan Ivanovich Dedov
Publicado: (2015)

On the centenary of the insulin discovery
por: I. I. Dedov, et al.
Publicado: (2021)

Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
por: Irina A. Proskurina, et al.
Publicado: (2016)

Arrhythmogenic effects of hypoglycemia in children and adolescents with type 1 diabetes mellitus
por: Dmitriy Nikitich Laptev, et al.
Publicado: (2013)

A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
por: Marina Vladimirovna Shestakova
Publicado: (2012)

Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
por: Elena Valer'evna Biryukova, et al.
Publicado: (2012)

Arrhythmogenic effects of hypoglycemia
por: Dmitriy Nikitich Laptev, et al.
Publicado: (2012)

Dose adjustment in insulin pump therapy: optimization of bolus calculator settings
por: Yury Ivanovich Filippov, et al.
Publicado: (2012)

Efficacy and safety of treatment with human insulin analogues in daily management of insulin naive patients with type 2 diabetes mellitus: results of multicenter 52-week observational study A1chive
por: Marina Vladimirovna Shestakova
Publicado: (2012)

Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2010)

Individual stepwise intensification of insulin analogue therapy in type 2 diabetes mellitus
por: Alexander Sergeevich Ametov, et al.
Publicado: (2012)

Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
por: Chan WB, et al.
Publicado: (2017)

Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
por: Tatiana Ivanovna Romantsova, et al.
Publicado: (2013)

Comparative analysis of glycemic control effectiveness and microvascular complications in patients with type 1 diabetes mellitus, treated with genetically engineered human insulin or human insulin analogues: A 10-year retrospective observational study
por: Marina V. Shestakova, et al.
Publicado: (2016)

The value of patient-reported outcomes in patients with type 2 diabetes mellitus receiving insulin therapy: assessment of quality of life and hypoglycemia problems
por: Tat'yana Ivanovna Ionova, et al.
Publicado: (2015)

The altered circadian pattern of basal insulin requirements – an early marker of autoimmune polyendocrine syndromes in type 1 diabetes mellitus
por: Pallayova Maria, et al.
Publicado: (2020)

Síndrome de hipoglicemia autoinmune: Primeros casos en Chile
por: Lanas,Alejandra, et al.
Publicado: (2015)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau IT, et al.
Publicado: (2017)

Association Between Knowledge of Hypoglycemia and Likelihood of Experiencing Hypoglycemia Among Patients with Insulin-Treated Diabetes Mellitus
por: Almigbal TH
Publicado: (2021)

Impaired hypoglycemia awareness in diabetes: epidemiology, mechanisms and therapeutic approaches
por: Vadim V. Klimontov
Publicado: (2018)

Special aspects of concentrated insulins: basic characteristics and research findings
por: Tatiana Y. Demidova, et al.
Publicado: (2019)

Age-adjustment of insulin pump settings in children and adolescents with type 1 diabetes mellitus
por: Dmitriy Nikitich Laptev, et al.
Publicado: (2013)

Insulin pump therapy in children with diabetes mellitus: practice of Krasnoyarsk Krai
por: Tatiana Evgen'evna Taranushenko, et al.
Publicado: (2012)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe S, et al.
Publicado: (2011)

RELUCTANCE OF PATIENTS WITH DIABETES MELLITUS TO INSULIN THERAPY; PSYCHOLOGICAL INSULIN RESISTANCE
por: Umair Ali, et al.
Publicado: (2021)

Hypoglycemia in type 2 diabetes patients treated with insulin: the advantages of continuous glucose monitoring
por: Vadim Valer'evich Klimontov, et al.
Publicado: (2014)

Prospective study of efficacy and safety of insulin pump therapy in children and adolescents
por: Andrey Olegovich Emel'yanov, et al.
Publicado: (2010)

91st Annual Conference on endocrine system diseases (ENDO, 2009), 10-13 June 2009, Washington
por: Natalya Nikitichna Volevodz
Publicado: (2009)

Basal insulin therapy in patients with type 2 diabetes mellitus and poor control of glycemia by oral hypoglycemic agents: results of direct comparative study of insulin analogs Lantus and Levemir
por: Alsu Gafurovna Zalevskaya, et al.
Publicado: (2010)

When basal insulin is not enough: successful strategies for insulin intensification in patients with type 2 diabetes mellitus
por: Elena V. Buryukova, et al.
Publicado: (2017)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan TJE, et al.
Publicado: (2021)

Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes
por: Eby EL, et al.
Publicado: (2015)

The results of open observational trial DIAMOND
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2011)

Early insulin therapy Coordination Council
por: Marina Vladimirovna Shestakova
Publicado: (2012)